Advertisement

Topics

Teva ahead 1% premarket on FDA acceptance of marketing application for Rituxan biosimilar

22:10 EDT 29 Jun 2017 | Topix

Teva Pharmaceutical Industries is up 1% premarket on light volume in response to the news that the FDA has accepted the Biologics License Application from commercialization partner Celltrion seeking approval of CT-P10, a biosimilar to Biogen and Roche's Rituxan . The agency's action date should be in Q1 2018.

Original Article: Teva ahead 1% premarket on FDA acceptance of marketing application for Rituxan biosimilar

NEXT ARTICLE

More From BioPortfolio on "Teva ahead 1% premarket on FDA acceptance of marketing application for Rituxan biosimilar"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...